8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


      Date of Report (Date of earliest event reported): September 25, 2002


                         Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                England and Wales
- --------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)


            0-29630                                         98-0359573
- -----------------------------              -------------------------------------
   (Commission File Number)                   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000
                                                       -------------------------



- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)







Item 5.  Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as
Exhibit 99.1 and incorporated by reference herein.

Item 7.  Financial Statements and Exhibits

      (c) Exhibits. The following exhibit is filed herewith:

99.1   Press Releases dated September 25, 2002



                                    SIGNATURE


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  September 26, 2002                       SHIRE PHARMACEUTICALS GROUP PLC



                                           By:  /s/ Angus Charles Russell
                                                --------------------------
                                                Name:  Angus Charles Russell
                                                Title:  Group Finance Director







                                  EXHIBIT INDEX


Number   Description

99.1     Press Releases dated September 25, 2002

EX-99

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP  UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com




Embargo 25 September 2002
10.30hrs (EST) 15:30hrs (UK Time)


Shire Pharmaceuticals Group plc (the "Company")

I have to inform you that the Company was notified on 25 September 2002 under
Sections 198 to 202 of the Companies Act that on 23 September 2002 FMR Corp. and
its direct and indirect subsidiaries and Fidelity International Limited and its
direct and indirect subsidiaries, both being non-beneficial holders, held solely
for investment purposes in aggregate 24,568,196 ordinary shares of (pound)0.05p
each in the capital of the Company. These holdings represent 5.08 per cent of
the issued ordinary share capital of the Company.



T May
Company Secretary


For further information please contact:

Global (outside US and Canada)
Clea Rosenfeld - Investor Relations                             +44 1256 894 160
US & Canada
Gordon Ngan - Investor Relations                                +1 450 978 7938

Notes to editors
Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international
specialty pharmaceutical company with a strategic focus on three therapeutic
areas - central nervous system disorders (CNS), oncology and anti-infectives.
Shire also has two platform technologies: advanced drug delivery and biologics.
Shire's core strategy is based on research and development combined with in
licensing and a focus on eight key pharmaceutical markets.

For further information on Shire, please visit the Company's website:
www.shire.com

THE "SAFE HARBOUR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. The statements in this press release that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event that
such risks or uncertainties materialise, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with the inherent uncertainty of pharmaceutical research, product
development and commercialisation, the impact of competitive products, patents,
government regulation and approval, and other risks and uncertainties detailed
from time to time


in periodic reports produced by Shire, including the Annual Report filed on Form
10K by Shire with the Securities and Exchange Commission.




Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP  UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com


Embargo 25 September 2002
10.00hrs (EST) 15:00hrs (UK Time)




Shire Pharmaceuticals Group plc (the "Company")

I have to inform you that the Company was notified on 24 September 2002 under
Sections 198 to 202 of the Companies Act that on 23 September 2002 Franklin
Resources, Inc. and its affiliates had holdings managed on behalf of investment
clients of 58,524,867 ordinary shares of (pound)0.05p each in the capital of the
Company. These holdings represent 12.1085 per cent of the issued ordinary share
capital of the Company.


T May
Company Secretary


For further information please contact:

Global (outside US and Canada)
Clea Rosenfeld - Investor Relations                             +44 1256 894 160
US & Canada
Gordon Ngan - Investor Relations                                +1 450 978 7938


Notes to editors
Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international
specialty pharmaceutical company with a strategic focus on three therapeutic
areas - central nervous system disorders (CNS), oncology and anti-infectives.
Shire also has two platform technologies: advanced drug delivery and biologics.
Shire's core strategy is based on research and development combined with in
licensing and a focus on eight key pharmaceutical markets.

For further information on Shire, please visit the Company's website:
www.shire.com


THE "SAFE HARBOUR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. The statements in this press release that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event that
such risks or uncertainties materialise, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with the inherent uncertainty of pharmaceutical research,




product development and commercialisation, the impact of competitive products,
patents, government regulation and approval, and other risks and uncertainties
detailed from time to time in periodic reports produced by Shire, including the
Annual Report filed on Form 10K by Shire with the Securities and Exchange
Commission.